AKYA AKOYA BIOSCIENCES INC

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to . It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at .

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit .



Investor Contact:

Priyam Shah
 

Media Contact:

Christine Quern
EN
28/10/2024

Underlying

AKYAAKOYA BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AKOYA BIOSCIENCES INC

 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Unveils a New Era in Spatial Content Innovation with...

Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research Launches the Mouse FFPE IO panel, optimized for pre-clinical immuno-oncology applications to drive translational research insights Expands the PhenoCode catalog with barcodes that enable ultrahigh-plex, 100-biomarker experiments, making scalable spatial biology research accessible for every lab M...

November 5, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Bioscience to Report Third Quarter 2024 Financial Results on Nov...

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024 MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to . It is recommended to register at least a day in ad...

October 28, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Groun...

Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya’s platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announc...

October 7, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Announces Scott Mendel as Chairman of the Board of D...

Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya’s board. Mr. Mendel has served as a member of Akoya’s board of directors since June 2021 and has over 30 years of financial and operational management experience. “I am thrilled to continue working wi...

October 3, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Reports Second Quarter 2024 Financial Results

Akoya Biosciences Reports Second Quarter 2024 Financial Results MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024. “Our second-quarter revenue showed a strong rebound with 26% sequential top-line growth and a stable year-over-year performance,” said Brian McKelligon, CEO of Akoya Biosciences. “We believe that Akoya’s platforms are poised to lead the spatial biology market from discovery to diagnostics, while we also position the company to achi...

August 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch